Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Yamaguchi University currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These cases are assigned to 4 distinct examiners, meaning each pending action is being reviewed by a different individual. The prosecution is distributed across 2 distinct art units, indicating some technical variety in the portfolio.
The busiest examiner for the portfolio is NG, JONATHAN K, who handles 1 pending office action. Since the busiest examiner pending count is 1, the 4 pending office actions are evenly split among the 4 distinct examiners. With 2 distinct art units involved, practitioners must navigate different technical groups within the Biotechnology & Pharmaceuticals sector. The lack of examiner overlap across the 4 pending office actions requires a strategy that accounts for four different individual perspectives, even though the cases are concentrated within only 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NG, JONATHAN K | 1 | 35.6% | +14.0% |
| XU, JUSTIN | 1 | 60.2% | +36.7% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| LU, CHENG | 1 | 54.1% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | AEDER, SEAN E | 23d overdue |
| 19134024 | ASTHMATIC DISEASE CONDITION ESTIMATION SERVER, ASTHMATIC DISEASE CONDITION ESTIMATION PROGRAM, AND ASTHMATIC DISEASE CONDITION ESTIMATION METHOD | NG, JONATHAN K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615748 | ANTIBODY CLEAVAGE SITE BINDING MOLECULE | CANELLA, KAREN A | 52d overdue |
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | AEDER, SEAN E | 23d overdue |
| 19134024 | ASTHMATIC DISEASE CONDITION ESTIMATION SERVER, ASTHMATIC DISEASE CONDITION ESTIMATION PROGRAM, AND ASTHMATIC DISEASE CONDITION ESTIMATION METHOD | NG, JONATHAN K | — |
| 18876950 | MANUAL MUSCLE STRENGTH TESTING DEVICE | XU, JUSTIN | — |
| 17603821 | CHIMERIC RECEPTOR THAT RECOGNIZES ENGINEERED SITE IN ANTIBODY | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 3619 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19134024 | ASTHMATIC DISEASE CONDITION ESTIMATION SERVER, ASTHMATIC DISEASE CONDITION ESTIMATION PROGRAM, AND ASTHMATIC DISEASE CONDITION ESTIMATION METHOD | NG, JONATHAN K | 3619 | §101§103§112 | Non-Final OA | — | Pending | May 29, 2025 |
| 18876950 | MANUAL MUSCLE STRENGTH TESTING DEVICE | XU, JUSTIN | — | §103 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | AEDER, SEAN E | 1642 | §102§103 | Final Rejection | 23d overdue | Pending | Jan 30, 2023 |
| 17615748 | ANTIBODY CLEAVAGE SITE BINDING MOLECULE | CANELLA, KAREN A | 1643 | §112 | Final Rejection | 52d overdue | Pending | Dec 01, 2021 |
| 17603821 | CHIMERIC RECEPTOR THAT RECOGNIZES ENGINEERED SITE IN ANTIBODY | LU, CHENG | 1642 | §112 | Non-Final OA | — | Pending | Oct 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial